Related Experiment Video

Updated: Jun 21, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Emerging therapies for relapsing multiple sclerosis

Jeffrey A Cohen1

  • 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA. cohenj@ccf.org

Archives of Neurology
|July 15, 2009
PubMed

Insights

New multiple sclerosis (MS) treatments are in development to address unmet needs. Emerging agents show promise in phase 2 trials for patients with relapsing MS experiencing continued disease activity or side effects.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Six agents are approved for relapsing multiple sclerosis (MS).
  • Current MS treatments may not fully control disease activity or prevent adverse effects in all patients.
  • There is a need for novel therapeutic strategies in MS management.

Purpose of the Study:

  • To review emerging therapeutic agents for relapsing multiple sclerosis.
  • To highlight agents that have demonstrated potential in phase 2 clinical trials.
  • To provide an overview of promising new treatments for MS.

Main Methods:

  • Literature review of phase 2 clinical trials.
  • Analysis of emerging agents for relapsing multiple sclerosis.
  • Synthesis of data on efficacy and safety profiles.

Main Results:

  • Several novel agents are under investigation for relapsing MS.
  • Emerging therapies have shown promise in early-stage clinical trials.
  • These agents may offer new options for patients with inadequate response or intolerance to existing therapies.

Conclusions:

  • The pipeline for relapsing multiple sclerosis therapeutics is robust.
  • Phase 2 trials indicate promising efficacy and safety for several new agents.
  • Further investigation in phase 3 trials is warranted to confirm the potential of these emerging MS treatments.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.